non-small cell lung cancer
GenDx, OSE Immunotherapeutics Ink Deal to Develop NGS CDx for Epitope-Based Cancer Vaccine
Under the deal, GenDx will develop and validate a companion diagnostic test for high-resolution typing of HLA-A*02 based on its IVDR-registered NGS products.
ChromaCode Lung Cancer Assay Shows Advantages in New Data at AMP as Company Eyes Next Applications
Premium
The firm is working with early adopters of its NSCLC kit as it develops new tests for cancer minimal residual disease monitoring and kidney transplant rejection.
A five-year, $4.6 million NCI grant will help the researchers advance their EFIRM electric field-based DNA detection platform toward potential regulatory approval.
In New TRACERx Data, Personalis MRD Test Shows Improved Sensitivity With Potential Clinical Impact
Premium
The data, some of the first available for the firm's NeXT Personal test, indicated that its higher analytical sensitivity could lead to better risk prediction than competing tests.
Thermo Fisher Scientific, Boehringer Ingelheim Partner on Companion Dx for Lung Cancer
The firms will develop multiple NGS-based companion diagnostic tests based on the Oncomine Dx Express Test and Oncomine Dx Target Test.